Spatiotemporal Tau Accumulation and Its Clinical Impact on PSP: Longitudinal Florzolotau (18F) PET
Preprint
Abstract
Background: Florzolotau (18F) positron emission tomography (florzolotau PET) enables high-contrast in vivo detection of four-repeat tau pathology in progressive supranuclear palsy (PSP), but whether longitudinal tau imaging reflects disease progression remains unclear. Objectives: To explore longitudinal tau accumulation using florzolotau PET and evaluate its association with clinical progression in PSP. Methods: A total of 26 patients with PSP (18 Richardson’s syndrome [PSP-RS], 8 non-RS) and 10 age- and sex-matched healthy controls (HCs) underwent florzolotau PET, MRI, and clinical assessments at baseline and after 1 year. Regional standardized uptake value ratios (SUVR) were extracted across 57 regions of interest. Partial least squares (PLS) multivariate analyses revealed regions with elevated baseline SUVR and longitudinal increase (ΔSUVR) in PSP relative to HCs, alongside regions where ΔSUVR was associated with changes in PSP Rating Scale scores. Results: At baseline, tau deposition was most prominent in the globus pallidus (GP) and midbrain in patients with PSP. Longitudinal tau increases were observed in the GP, frontoparietal cortex, and cerebellum, whereas minimal progression was observed in the midbrain. GP tau accumulation exhibited the strongest association with clinical progression in the PLS model among PSP-RS and a univariate correlation (Spearman’s ρ = 0.674, p = 0.002). Conclusions: This study provides in vivo evidence of the spatiotemporal progression of tau pathology in PSP. In the GP, tau accumulation emerges early and continues to rise with clinical deterioration. These findings support the utility of florzolotau PET for monitoring disease progression and as a biological outcome measure in tau-targeted therapeutic trials.Keywords
This publication has 48 references indexed in Scilit:
- Longitudinal monitoring of tau aggregation in progressive supranuclear palsy with [ 18 F]PI‐2620 PETAlzheimer's & Dementia, 2026
- Assessment of 18F-PI-2620 as a Biomarker in Progressive Supranuclear PalsyJAMA Neurology, 2020
- Diagnosis Across the Spectrum of Progressive Supranuclear Palsy and Corticobasal SyndromeJAMA Neurology, 2020
- In vivo binding of a tau imaging probe, [11C]PBB3, in patients with progressive supranuclear palsyMovement Disorders, 2019
- MRI Outperforms [18F]AV‐1451 PET as a Longitudinal Biomarker in Progressive Supranuclear PalsyMovement Disorders, 2018
- 18F‐flortaucipir tau positron emission tomography distinguishes established progressive supranuclear palsy from controls and Parkinson disease: A multicenter studyAnnals of Neurology, 2017
- Radiological biomarkers for diagnosis in PSP: Where are we and where do we need to be?Movement Disorders, 2017
- Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteriaMovement Disorders, 2017
- The phenotypic spectrum of progressive supranuclear palsy: A retrospective multicenter study of 100 definite casesMovement Disorders, 2014
- Tideglusib reduces progression of brain atrophy in progressive supranuclear palsy in a randomized trialMovement Disorders, 2014